Search for Clinical Trial Results

Sponsored By

Purpura, Thrombotic Thrombocytopenic - 25 Studies Found

Status Study
Withdrawn Study Name: Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura
Condition: Purpura, Thrombotic Thrombocytopenic
Date: 2012-12-12
Interventions:
  • Drug: Octaplas infusion and placebo (group 1)

Terminated Study Name: IdeS in Asymptomatic Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients
Condition: Purpura, Thrombotic Thrombocytopenic
Date: 2016-07-27
Interventions: Biological: HMed-IdeS One dose of 0.25 mg/kg BW HMed-IdeS on study day 0. Following and evaluation of ef
Recruiting Study Name: Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)
Condition: Thrombotic Thrombocytopenic Purpura
Date: 2009-08-04
Interventions: Drug: Danazol Danazol 600 mg PO will be initiated with plasma exchange and corticosteroids at the time o
Completed Study Name: ADAMTS13 in Thrombotic Thrombocytopenic Purpura
Condition: Thrombotic Thrombocytopenic Purpura
Date: 2007-01-24
Withdrawn Study Name: Use of Rituximab Treatment in Addition to Standard Care for Newly Presenting Thrombotic Thrombocytopenic Purpura
Condition: Thrombotic Thrombocytopenic Purpura
Date: 2005-11-07
Interventions: Drug: Rituximab Rituximab will be administered immediately after pheresis to minimize the amount of Ritu
Completed Study Name: Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura
Condition: Thrombotic Thrombocytopenic Purpura
Date: 2009-05-22
Interventions: Drug: rituximab Patients will be treated according to the recommendations of the Reference Centre for th
Active, not recruiting Study Name: Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP)
Condition: Thrombotic Thrombocytopenic Purpura
Date: 2008-07-09
Interventions:
  • Drug: Cyclosporine 2-3 mg/kg o
Completed Study Name: Study to Assess Efficacy and Safety of Anti-von Willebrand Factor Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (TTP)
Condition: Thrombotic Thrombocytopenic Purpura
Date: 2010-06-25
Interventions:
  • Biological: anti-vWF Nanobody

Recruiting Study Name: Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura
Condition: Acquired Thrombotic Thrombocytopenic Purpura
Date: 2015-09-14
Interventions:
  • Biological: caplacizumab Other
Recruiting Study Name: The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP)
Condition: Thrombotic Thrombocytopenic Purpura (TTP)
Date: 2009-07-09
Interventions: Drug: Rituximab Concentrate for solution for infusion, Intravenous use, 375mg/m2, Maximum 8 weekly infus
Next >>>